Kura Onkoloji A.Ş. 2026 2. Çeyrek Kazanç Çağrı Özeti

Kura Oncology, Inc. Q2 2026 Earnings Call Summary

Moby Intelligence

Thu, August 13, 2026 at 4:26 AM GMT+3 3 min read

• KURA +1.51%

Strategic Performance and Market Positioning

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

• Achieved majority share of new patient starts in the relapsed/refractory NPM1-mutant AML menin inhibitor market within the second full commercial quarter, despite being second to market.

• Management attributes rapid adoption to a differentiated product profile characterized by predictable safety, dosing convenience, and lack of meaningful myelosuppression when combined with intensive chemotherapy.

• Strategic focus is shifting toward establishing Ziftomenib as a foundational therapy through combinations with standards of care, supported by frontline data showing a 96% ORR in certain populations.

• Darlifarnib is emerging as a second wholly owned strategic pillar, demonstrating the ability to enhance targeted therapy backbones in renal cell carcinoma and KRAS-mutated solid tumors.

• Commercial execution is driven by high engagement with over 90% of top-priority AML accounts and successful navigation of market access, covering over 95% of lives.

• Performance in the quarter was bolstered by physician-initiated combination use, which accounted for approximately 40% of new patient starts, signaling future treatment paradigm shifts.

Clinical Milestones and Strategic Outlook

• Anticipate multiple clinical updates in the second half of 2026, including preliminary data for Ziftomenib combinations with gilteritinib and quizartinib.

• The pivotal KOMET-017 Phase 3 trial remains on track for top-line results in 2028, utilizing a 'one-stop-shop' design to accrue both intensive and non-intensive chemotherapy patients.

• Plan to initiate a darlifarnib platform study in second-line or later KRAS-mutant pancreatic cancer in the first half of 2027.

• Current cash reserves and anticipated collaboration payments are expected to fund the Ziftomenib AML program through its first Phase 3 readout in 2028.

• Management intends to maintain disciplined capital allocation, prioritizing registrational paths for both franchises while remaining open to selective strategic collaborations.

Operational and Financial Context

• Reported $9.1 million in net product revenue for COMZIFTI, exceeding internal expectations for the second full quarter of launch.

• Maintained collaboration revenue guidance of $45 million to $55 million for 2026, reflecting non-cash accounting for the Kyowa Kirin partnership.

• R&D expenses slightly decreased year-over-year, reflecting a disciplined approach to pipeline expansion despite increased clinical activity.

• Identified a potential total addressable market of $7 billion for Ziftomenib across the AML treatment continuum, assuming successful frontline expansion.

Q&A Session Insights

Market share dynamics and competition in the NPM1-mutant AML space

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

• Management clarified that while competitors may claim high overall starts, Kura holds the majority in the specific NPM1-mutant segment, which is the larger commercial opportunity.

• Noted a 35% quarter-over-quarter growth in new patient starts and a 60% growth in total prescriptions, contrasting with a perceived decline in competitor starts.

Rationale for exploring Ziftomenib in non-NPM1/KMT2A AML subtypes

• Management believes up to 50% of AML cases may be menin-dependent due to high MEIS1 expression, expanding the potential patient population beyond current genetic markers.

• Early clinical signals, including a complete response in a CEBPA/RUNX1 patient, support the exploratory analysis of broader menin-dependent AML subtypes.

Strategic funding and collaboration plans for the darlifarnib franchise

• Management prefers to retain full ownership of darlifarnib at this stage to maximize value, noting its potential as a 'blockbuster' asset alongside Ziftomenib.

• The timing of investment decisions for darlifarnib registrational studies is designed to align with the 2028 Ziftomenib Phase 3 data readouts.

Physician-initiated combination use and its impact on commercial strategy

• Approximately 40% of new starts are in combination with venetoclax, azacitidine, or FLT3 inhibitors, which management views as a validation of the drug's 'practical fit'.

• While promoting only the monotherapy label, Kura is accelerating data generation for these combinations to support physician choice and future label expansions.